1,064 results match your criteria Nephrogenic Systemic Fibrosis


Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Ann Intern Med 2020 Jun 23. Epub 2020 Jun 23.

Duke University School of Medicine and Durham Veterans Affairs Health Care System, Durham, North Carolina (J.W.W., K.M.G.).

Background: The risk for nephrogenic systemic fibrosis (NSF) after exposure to newer versus older gadolinium-based contrast agents (GBCAs) remains unclear.

Purpose: To synthesize evidence about NSF risk with newer versus older GBCAs across the spectrum of kidney function.

Data Sources: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science for English-language references from inception to 5 March 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/M20-0299DOI Listing

Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology.

J Neuroradiol 2020 06 18. Epub 2020 Jun 18.

MRI center, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, CREATIS-LRMN, CNRS/UMR/5220-INSERM U630, Villeurbanne, France.

Gadolinium-based contrast agents (GBCAs) are used in up to 35% of magnetic resonance imaging (MRI) examinations and are associated with an excellent safety profile. Nevertheless, two main issues have arisen in the last two decades: the risk of nephrogenic systemic fibrosis and the risk of gadolinium deposition and retention. As a first step, this article reviews the different categories of GBCAs available in neuroradiology, their issues, and provides updates regarding the use of these agents in routine daily practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurad.2020.05.008DOI Listing

Sclerodermalike syndromes: Great imitators.

Clin Dermatol 2020 Mar - Apr;38(2):235-249. Epub 2019 Oct 24.

Department of Rheumatology and Immunology, University of Pécs Clinical Center, Pecs, Hungary. Electronic address:

Sclerodermalike syndromes (SLSs) comprise diseases with mucin deposition (eg, scleromyxedema, scleredema), with eosinophilia (eg, eosinophilic fasciitis), metabolic or biochemical abnormalities (eg, nephrogenic systemic fibrosis), or endocrine disorders (eg, POEMS syndrome, or polyneuropathy, organomegaly, endocrinopathy, monoclonal lymphoproliferative disorder, and hypothyroidism). Chronic graft-versus-host disease may also show sclerodermalike skin changes. Inherited progeria syndromes with early aging (eg, Werner syndrome) and a heterogeneous group of hereditary disorders with either skin thickening (eg, stiff skin syndrome) or atrophy and tightening (eg, acrogeria) can also imitate classic systemic sclerosis (SSc). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.010DOI Listing
October 2019

Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis.

Radiology 2020 May 26:200073. Epub 2020 May 26.

From the Department of Medical Imaging, The Ottawa Hospital, 1053 Carling Ave, Room C159, Ottawa, ON, Canada K1Y 4E9 (N.S., D.W.); Department of Diagnostic Imaging, Juravinski Cancer Centre, Hamilton, Canada (C.B.v.d.P.); Clinical Research Unit, Children's Hospital of Eastern Ontario, Ottawa, Canada (A.K.T.); Department of Radiology, Sunnybrook Health Sciences Centre, Toronto, Canada (P.J.M.); Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY (S.W.); and Department of Radiology, University of Michigan Medical Center, Ann Arbor, Mich (M.S.D.).

Background Gadoxetic acid is classified by the American College of Radiology as a group III gadolinium-based contrast agent (GBCA), which indicates that there are limited data regarding nephrogenic systemic fibrosis (NSF) risk, but there are few if any unconfounded cases of NSF. Purpose To perform a systematic review and meta-analysis of gadoxetic acid adverse events, including immediate hypersensitivity reactions, NSF, and intracranial gadolinium retention. Materials and Methods Original research studies, case series, and case reports that reported adverse events in patients undergoing gadoxetic acid-enhanced MRI were searched in MEDLINE (1946-2019), Embase (1947-2019), CENTRAL (March 2019), and Scopus (1946-2019). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2020200073DOI Listing

Risks and Benefits of Gadolinium-Based Contrast Enhanced MRI.

Semin Ultrasound CT MR 2020 Apr 7;41(2):260-274. Epub 2020 Mar 7.

Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX.

The responsible use of gadolinium based contrast agents (GBCAs) requires a balance between safety and clinical utility. While nephrogenic systemic fibrosis has been associated with most linear GBCAs few, if any, new cases have been verified since the successful implementation of screening programs to detect renal impairment and prevent susceptible patients from receiving these higher-risk agents. The likelihood of developing nephrogenic systemic fibrosis has been shown to be negligible with macrocyclic agents, prompting the American College of Radiology and other regulatory agencies to suggest that no screening is necessary when they are used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.sult.2020.03.001DOI Listing

Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI.

Semin Ultrasound CT MR 2020 Apr 10;41(2):170-182. Epub 2019 Dec 10.

University of Texas MD Anderson Cancer Center, Division of Diagnostic Imaging, Houston, TX.

The responsible use of gadolinium-based contrast agents (GBCAs) requires a balance between safety and clinical utility. While nephrogenic systemic fibrosis (NSF) has been associated with most linear GBCAs few, if any, new cases have been verified since the successful implementation of screening programs to detect renal impairment and prevent susceptible patients from receiving these higher-risk agents. The likelihood of developing nephrogenic systemic fibrosis has been shown to be negligible with macrocyclic agents, prompting the American College of Radiology and other regulatory agencies to suggest that no screening is necessary when they are used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.sult.2019.12.005DOI Listing

Strategic reconstruction of macrophage-derived extracellular vesicles as a magnetic resonance imaging contrast agent.

Biomater Sci 2020 May 17;8(10):2887-2904. Epub 2020 Apr 17.

Department of Chemistry, Nanotechnology Innovation Center of Kansas State (NICKS), Kansas State University, Manhattan, KS 66506, USA.

A contrast agent (CA) in magnetic resonance imaging (MRI) is now an essential add-on to obtain high-quality contrast-enhanced anatomical images for disease diagnosis and monitoring the treatment response. However, the rapid elimination of CAs by the immune system and excretion by the renal route has limited its application. As a result, the CA dose for effective contrast is ever-increasing, resulting in toxic side effects such as gadolinium (Gd) related nephrogenic systemic fibrosis (NSF) toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/d0bm00128gDOI Listing

Scleroderma mimics - Clinical features and management.

Best Pract Res Clin Rheumatol 2020 Feb 5;34(1):101489. Epub 2020 Mar 5.

Centre for Rheumatology, Royal Free Campus, University College London, Rowland Hill Street, London NW3 2PF, UK. Electronic address:

Systemic sclerosis is a severe immune-mediated rheumatic disease by virtue of its clinical impact and mortality. There are a number of other sclerosing skin diseases that should be considered in the differential diagnosis and these are important because they may require specialist investigation and management. In addition, long-term follow up of the different conditions should reflect the risk of associated complications and anticipated duration of therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.berh.2020.101489DOI Listing
February 2020

Radiocontrast Toxicity.

Authors:
Staci Leisman

Adv Chronic Kidney Dis 2020 01;27(1):50-55

Division of Nephrology, Department of Medicine, Mount Sinai Hospital/Icahn School of Medicine, New York, NY. Electronic address:

Intravenous and intraarterial contrast media are invaluable tools in the diagnosis of anatomic lesions. However, they have been associated with deleterious renal events, ranging from acute kidney injury (iodinated contrast) to nephrogenic systemic fibrosis (gadolinium-containing agents). Contrast-associated acute kidney injury has a wide incidence, likely due to differences in populations studied, with incidence likely overstated due to comorbid conditions at the time of contrast exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ackd.2019.08.002DOI Listing
January 2020

Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.

AJNR Am J Neuroradiol 2020 03 27;41(3):393-399. Epub 2020 Feb 27.

Office of Pharmacovigilance and Epidemiology (C.W.), US Food and Drug Administration, Silver Spring, Maryland.

Background And Purpose: Nephrogenic systemic fibrosis following administration of intravenous gadobenate during MR imaging is rare. This study aimed to analyze any nephrogenic systemic fibrosis-related risks and quantify skin gadolinium levels in patients with impaired renal function but without nephrogenic systemic fibrosis who had received gadobenate.

Materials And Methods: In this retrospective study with a prospective skin biopsy phase, patients with estimated glomerular filtration rates of <60 mL/min/1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3174/ajnr.A6448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077886PMC

Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.

Magn Reson Imaging 2020 Jul 26;70:1-4. Epub 2020 Feb 26.

Surgical, Medical and Dental Department of Morphological Sciences, Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy; Nephrology Dialysis and Transplant Unit, University of Modena and Reggio Emilia, AOU Policlinico of Modena, Modena, Italy. Electronic address:

Purpose: Nephrogenic system fibrosis (NSF) is a rare complication detected in patients with renal insufficiency exposed to gadolinium-based contrast agents (GBCAs). The aim of our study is to evaluate the prevalence of NSF in a cohort of patients on renal replacement treatment who underwent GBCA-enhanced magnetic resonance imaging (MRI).

Method: We retrospectively reviewed all the charts of kidney transplant (KT) recipients, patients on hemodialysis (HD) and peritoneal dialysis (PD) who received a uniform protocol for contrast material enhanced-MRI with gadoteric acid at our center from January 2004 to December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mri.2020.02.012DOI Listing

The Risk of Nephrogenic Systemic Fibrosis in Group II and III Gadolinium-Based Contrast Agents.

Authors:
Andreu F Costa

Can Assoc Radiol J 2020 Jan 31:846537119888408. Epub 2020 Jan 31.

Department of Diagnostic Radiology, QE II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0846537119888408DOI Listing
January 2020

Multimodal indirect imaging signs of pulmonary embolism.

Br J Radiol 2020 Apr 21;93(1108):20190635. Epub 2020 Jan 21.

Department of Radiology, Rio de Janeiro Federal University, Rio de Janeiro, Brazil.

The clinical diagnosis of pulmonary embolism is often difficult, as symptoms range from syncope and chest pain to shock and sudden death. Adding complexity to this picture, some patients with non-diagnosed pulmonary embolism may undergo unenhanced imaging examinations for a number of reasons, including the prevention of contrast medium-related nephrotoxicity, anaphylactic/anaphylactoid reactions and nephrogenic systemic fibrosis, as well as due to patients' refusal or lack of venous access. In this context, radiologists' awareness and recognition of indirect signs are cornerstones in the diagnosis of pulmonary embolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20190635DOI Listing

Is it time to relax nephrogenic systemic fibrosis guidelines and safely offer magnetic resonance imaging to more patients?

Quant Imaging Med Surg 2019 Nov;9(11):1918-1921

Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/qims.2019.10.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902148PMC
November 2019

The extra miles on preventing nephrogenic systemic fibrosis.

Quant Imaging Med Surg 2019 Nov;9(11):1911-1913

Diagnostic Radiology and Nuclear Medicine Department, Gunma University Graduate School of Medicine, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/qims.2019.09.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902147PMC
November 2019

Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

JAMA Intern Med 2019 Dec 9. Epub 2019 Dec 9.

Department of Radiology, University of Michigan, Ann Arbor.

Importance: Risk of nephrogenic systemic fibrosis (NSF) to individual patients with stage 4 or 5 chronic kidney disease (CKD; defined as estimated glomerular filtration rate of <30 mL/min/1.73 m2) who receive a group II gadolinium-based contrast agent (GBCA) is not well understood or summarized in the literature.

Objective: To assess the pooled risk of NSF in patients with stage 4 or 5 CKD receiving a group II GBCA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamainternmed.2019.5284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902198PMC
December 2019

Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.

Radiographics 2020 Jan-Feb;40(1):153-162. Epub 2019 Dec 6.

From the Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar St, Tompkins East TE-2, New Haven, CT 06520.

Gadolinium-based contrast agents (GBCAs) have an excellent safety profile. However, over the last 2 decades, two specific concerns have surfaced. GBCAs are associated with nephrogenic systemic fibrosis (NSF) and tissue retention of gadolinium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.2020190110DOI Listing
December 2019

Gadolinium Retention and Breast MRI Screening: More Harm Than Good?

AJR Am J Roentgenol 2020 02 4;214(2):324-327. Epub 2019 Dec 4.

Unit of Radiology, IRCCS Policlinico San Donato, Milan, Italy.

The purpose of this article is to describe the risk-benefit balance of contrast-enhanced breast MRI (CE-BMRI) screening. CE-BMRI confers risk of effects associated with administration of gadolinium-based contrast agents (GBCAs), including nephrogenic systemic fibrosis and gadolinium retention. The risk-benefit balance of CE-BMRI screening is favorable for carriers of , , or other deleterious mutations women who have undergone thoracic irradiation; and women at 20% or greater lifetime risk of breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.19.21988DOI Listing
February 2020

Contraindications and adverse effects in abdominal imaging.

Med Ultrason 2019 Nov;21(4):456-463

Medizinische Klinik 2, Caritas-Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany, Ultrasound Department, First Affiliated Hospital of Zhengzhou University, China.

Ultrasound (US), computed-tomography (CT) and magnetic resonance imaging (MRI) are the most frequently used imaging techniques in abdominal pathology. US plays a pivotal role in evaluating abdominal disease, sometimes being sufficient for a complete diagnosis and has virtually no contraindications. The usage of US contrast agents will add useful diagnostic information in both hepatic and non-hepatic pathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11152/mu-2145DOI Listing
November 2019

Noncontrast Magnetic Resonance Angiography Clinical Application in Pre-Liver Transplant Recipients With Impaired Renal Function.

Liver Transpl 2020 Feb 6;26(2):196-202. Epub 2020 Jan 6.

Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Image evaluation of the vascular architecture is essential before living donor liver transplantation (LDLT). However, the use of contrast-enhanced study in recipients with impaired renal function is limited due to the risk of acute kidney injury and nephrogenic systemic fibrosis. Therefore, a contrast medium-free method is both valuable and necessary for preoperative vascular evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.25677DOI Listing
February 2020

Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?

Clin Toxicol (Phila) 2020 Mar 30;58(3):151-160. Epub 2019 Oct 30.

General Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Gadolinium-based contrast agents are widely used for magnetic resonance imaging and, until recently, had been generally considered to have an excellent safety profile in patients with normal renal function. Nephrogenic systemic fibrosis is a well-established disease process involving fibrosis of the skin and internal organs seen in some patients with severely impaired renal function following exposure to these agents. Following reports that individuals with normal renal function may experience gadolinium deposition within brain and bone tissue, the term "gadolinium deposition disease" has been proposed and the use of chelating agents has been recommended to treat this "disease". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15563650.2019.1681442DOI Listing

Nephrogenic systemic fibrosis: the end of the story?

Authors:
Hana Malikova

Quant Imaging Med Surg 2019 Aug;9(8):1470-1474

Department of Radiology, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/qims.2019.07.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732068PMC
August 2019
1 Read

Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging.

Wiley Interdiscip Rev Nanomed Nanobiotechnol 2020 Jan 5;12(1):e1580. Epub 2019 Sep 5.

Department of Chemistry, Kansas State University, Manhattan, Kansas.

Magnetic resonance imaging (MRI) is a routinely used imaging technique in medical diagnostics, which is further enhanced with the use of contrast agents (CAs). The most commonly used CAs are gadolinium-based contrast agents (GBCAs), in which gadolinium (Gd) is chelated with organic chelating agents (linear or cyclic). However, the use of GBCA is related to toxic side effect due to the release of free Gd ions from the chelating agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wnan.1580DOI Listing
January 2020
1 Read

Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging-a comprehensive overview.

Insights Imaging 2019 Aug 23;10(1):84. Epub 2019 Aug 23.

Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden.

Gadolinium-based contrast agents (GBCAs) increase lesion detection and improve disease characterization for many cerebral pathologies investigated with MRI. These agents, introduced in the late 1980s, are in wide use today. However, some non-ionic linear GBCAs have been associated with the development of nephrogenic systemic fibrosis in patients with kidney failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13244-019-0771-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708018PMC
August 2019
5 Reads

Non-Contrast-Enhanced Carotid MRA: Clinical Evaluation of a Novel Ungated Radial Quiescent-Interval Slice-Selective MRA at 1.5T.

AJNR Am J Neuroradiol 2019 09 8;40(9):1529-1537. Epub 2019 Aug 8.

From the Department of Radiology and Neuroradiology (S.P., M.H., U.J.-K., N.L., M.B., O.J., M.S.R.), University Medical Center Schleswig-Holstein, Kiel University, Kiel, Germany

Background And Purpose: Non-contrast-enhanced MRA techniques have experienced a renaissance due to the known correlation between the use of gadolinium-based contrast agents and the development of nephrogenic systemic fibrosis and the deposition of gadolinium in some brain regions. The purpose of this study was to assess the diagnostic performance of ungated non-contrast-enhanced radial quiescent-interval slice-selective MRA of the extracranial supra-aortic arteries in comparison with conventional contrast-enhanced MRA in patients with clinical suspicion of carotid stenosis.

Materials And Methods: In this prospective study, both MRA pulse sequences were performed in 31 consecutive patients (median age, 68. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3174/ajnr.A6171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728222PMC
September 2019
2 Reads

The Transition from Metal-Based to Metal-Free Contrast Agents for Magnetic Resonance Imaging Enhancement.

Bioconjug Chem 2019 09 19;30(9):2264-2286. Epub 2019 Aug 19.

Cixi Institute of Biomedical Engineering, CAS Key Laboratory of Magnetic Materials and Devices, & Key Laboratory of Additive Manufacturing Materials of Zhejiang Province , Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences , Ningbo 315201 , P.R. China.

Magnetic resonance imaging (MRI) has received significant attention as the noninvasive diagnostic technique for complex diseases. Image-guided therapeutic strategy for diseases such as cancer has also been at the front line of biomedical research, thanks to the innovative MRI, enhanced by the prior delivery of contrast agents (CAs) into patients' bodies through injection. These CAs have contributed a great deal to the clinical utility of MRI but have been based on metal-containing compounds such as gadolinium, manganese, and iron oxide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.bioconjchem.9b00499DOI Listing
September 2019
3 Reads
4.513 Impact Factor

Pictorial review on abdominal applications of ferumoxytol in MR imaging.

Abdom Radiol (NY) 2019 10;44(10):3273-3284

Department of Radiology, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, White 270, Boston, MA, 02114, USA.

Though gadolinium-based contrast agents are the most widely used contrast media in MR for clinical use, problems with nephrogenic systemic fibrosis and tissue deposition render their safety debatable, at least in a selected patient population. Ferumoxytol has the potential to be used as an alternate contrast medium for various clinical applications across multiple organs. It has prolonged intravascular signal and delayed intracellular macrophage uptake which are unique properties compared to gadolinium-based agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-02163-4DOI Listing
October 2019
6 Reads

Launching lollipops? Perforating osteoma cutis in nephrogenic systemic fibrosis.

J Cutan Pathol 2019 Jul;46(7):467-470

Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13409DOI Listing
July 2019
6 Reads

[Sclerosing skin diseases].

Internist (Berl) 2019 Aug;60(8):783-791

Hautklinik, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland.

Sclerosing skin manifestations are more a symptom than a diagnosis and must therefore be meticulously clarified. Systemic scleroderma as a multiorgan disease must be distinguished from localized scleroderma or morphea because in addition to a different clinical picture they have a different prognosis and necessitate other therapeutic procedures. Rare sclerosing skin diseases with implications for internal medicine are eosinophilic fasciitis, Buschke's scleredema adultorum, scleromyxedema and nephrogenic systemic fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-019-0643-2DOI Listing
August 2019
16 Reads

Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.

J Magn Reson Imaging 2020 Feb 9;51(2):607-614. Epub 2019 Jul 9.

Central Institute for Radiology and Neuroradiology, Krankenhaus Nordwest, Frankfurt am Main, Germany.

Background: Nephrogenic systemic fibrosis (NSF) is a rare life-threatening condition strongly associated with the administration of gadolinium-based contrast agents in patients with severe or endstage renal impairment.

Purpose: To prospectively determine the incidence of NSF in patients with renal impairment after administration of gadoterate meglumine.

Study Type: Prospective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.26851DOI Listing
February 2020
3 Reads

Gadolinium chloride promotes proliferation of HEK293 human embryonic kidney cells by activating EGFR/PI3K/Akt and MAPK pathways.

Biometals 2019 08 8;32(4):683-693. Epub 2019 Jul 8.

State Key Laboratory of Natural and Biomimetic Drugs, Peking University School of Pharmaceutical Sciences, Beijing, 100191, People's Republic of China.

Prolonged exposure to gadolinium-based contrast agents has been reported to trigger nephrogenic systemic fibrosis in end stage renal disease patients. However, the exact molecular mechanisms are not fully understood, and no effective therapy is available to date. In the present study, we report that gadolinium chloride (Gd) concentration- and time-dependently promoted the proliferation of HEK293 human embryonic kidney cells by increasing DNA synthesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10534-019-00205-4DOI Listing
August 2019
5 Reads

Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study.

Int J Cardiol 2019 10 4;293:272-277. Epub 2019 Jun 4.

Birmingham Cardiorenal Group, Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom of Great Britain and Northern Ireland.

Increased native myocardial T1 times in chronic kidney disease (CKD) may be due to diffuse interstitial myocardial fibrosis (DIF) or due to interstitial edema/inflammation. Concerns relating to nephrogenic systemic fibrosis with gadolinium-based contrast agents (GBCA) limit their use in end-stage kidney disease (ESKD) to measure extracellular volume (ECV) and characterise myocardial fibrosis. This study aimed to examine stability of myocardial T1 and T2 times before, and within 2 months after kidney transplantation; a time frame when volume status normalises but myocardial remodelling is unlikely to have occurred, and to compare these with ECV using GBCA after transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2019.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723623PMC
October 2019
12 Reads

Virtual Elimination of Nephrogenic Systemic Fibrosis: A Medical Success Story with a Small Asterisk.

Radiology 2019 Aug 2;292(2):387-389. Epub 2019 Jul 2.

From the Department of Radiology, Michigan Medicine, 1500 E Medical Center Dr, B2-A209A, Ann Arbor, MI 48109.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019191158DOI Listing
August 2019
1 Read

A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.

Radiology 2019 08 2;292(2):376-386. Epub 2019 Jul 2.

From the Department of Radiology, Weill Cornell Medical College & New York Presbyterian Hospital, 416 E 55th St, New York, NY 10022 (H.A., Y.Z., M.R.P.); Department of Radiology, Wayne State University/Detroit Medical Center, Detroit, Mich (Y.C.); Department of Children and Adolescent Psychiatry, Aarhus University Hospital, Aarhus, Denmark (T.R.E.); and Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY (M.R.P.).

Background Although nephrogenic systemic fibrosis (NSF) affects the use of gadolinium-based contrast agents (GBCAs) in MRI, there continues to be limited knowledge because of the small number of patients with NSF. Purpose To perform a systematic review of NSF. Materials and Methods PubMed database was searched by using the term "Nephrogenic systemic fibrosis" from January 2000 to February 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019182916DOI Listing
August 2019
15 Reads

Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.

Can Assoc Radiol J 2019 Aug 27;70(3):226-232. Epub 2019 Jun 27.

Division of Nephrology, Department of Medicine and Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

In 2017, the Canadian Association of Radiologists issued a clinical practice guideline (CPG) regarding the use of gadolinium-based contrast agents (GBCAs) in patients with acute kidney injury (AKI), chronic kidney disease (CKD), or on dialysis due to mounting evidence indicating that nephrogenic systemic fibrosis (NSF) occurs with extreme rarity or not at all when using Group II GBCAs or the Group III GBCA gadoxetic acid (compared to first generation Group I linear GBCAs). One of the goals of the work group was to re-evaluate the CPG after 24 months to determine the effect of more liberal use of GBCA on reported cases of NSF in patients with AKI, CKD Stage 4 or 5 (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m), or those that are dialysis-dependent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carj.2019.04.001DOI Listing
August 2019
7 Reads

The first case of coexistence of calciphylaxis and nephrogenic systemic fibrosis with different localizations in a hemodialysis patient.

Nefrologia 2020 Jan - Feb;40(1):104-106. Epub 2019 Jun 8.

Department of Dermatology, Medeniyet University, Faculty of Medicine, Istanbul, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nefro.2019.03.011DOI Listing
June 2019
10 Reads

Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications.

RSC Adv 2019 May 10;6(51):45462-45474. Epub 2016 May 10.

NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore (NUS), Singapore.

Manganese oxide nanoparticles (MONs) have received growing attention as alternative MRI contrast agents due to the association of commercial gadolinium-based contrast agents with nephrogenic systemic fibrosis. Since the seminal publication first describing the use of MONs as positive contrast agents, there is an ongoing impetus to develop MONs of higher signal intensity for better diagnostic efficacy. Indeed, various MON-based nanoprobe designs have been proposed, such as the employment of a mesoporous nanomaterial with MONs evenly dispersed within, or the traditional coating of a biocompatible layer onto the surface of MONs to form a core-shell configuration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/C6RA04421BDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542684PMC
May 2019
19 Reads

Effects of gadolinium and gadolinium chelates on intracellular calcium signaling in sensory neurons.

Neurosci Lett 2019 08 29;707:134295. Epub 2019 May 29.

Physiology Department, Faculty of Medicine, Firat University, Elazig, Turkey. Electronic address:

Magnetic resonance imaging (MRI) employs gadolinium chelates as contrast agents to provide signal enhancement in radiological images. However, the instability of the chelates presents a challenge as the released gadolinium ion (Gd) from the chelates becomes toxic to the surrounding biological tissue. Chelates such as gadodiamide, gadoterate meglumine, gadobutrol and gadobenate dimeglumine are common contrast agents used in clinics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neulet.2019.134295DOI Listing
August 2019
4 Reads

Toxicological Risk Assessments of Iron Oxide Nanocluster- and Gadolinium-Based T1MRI Contrast Agents in Renal Failure Rats.

ACS Nano 2019 06 4;13(6):6801-6812. Epub 2019 Jun 4.

Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou 310058 , China.

Gadolinium-based contrast agents (GBCAs) are widely used for T1-weighted magnetic resonance imaging (MRI) in clinic diagnosis. However, a major drawback of GBCAs is that they can increase the toxicological risk of nephrogenic systemic fibrosis (NSF) in patients with advanced renal dysfunction. Hence, safer alternatives to GBCAs are currently in demand, especially for patients with renal diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsnano.9b01511DOI Listing
June 2019
20 Reads
12.881 Impact Factor

Feasibility of using half-dose Gd-BOPTA for delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at the knee, compared with standard-dose Gd-DTPA.

J Magn Reson Imaging 2020 01 29;51(1):144-154. Epub 2019 May 29.

Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, University Medicine Rostock, Rostock, Germany.

Background: We sought to replace full-dose Gd-DTPA with safer and lower-dose contrast agents for delayed gadolinium-enhanced MRI of cartilage (dGEMRIC). Gd-BOPTA has a lower intrinsic nephrogenic systemic fibrosis risk and a 2-fold higher relaxivity at 3T; thus, the contrast agent dose may be halved, further reducing contrast agent-dependent risks.

Purpose: To compare the feasibility of using half-dose, high-relaxivity Gd-BOPTA vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.26816DOI Listing
January 2020
11 Reads

Noncontrast Magnetic Resonance Angiography for the Diagnosis of Peripheral Vascular Disease.

Circ Cardiovasc Imaging 2019 05;12(5):e008844

Departments of Medicine and Radiology, University Hospitals, Harrington Heart & Vascular Institute, Case Western Reserve University, Cleveland OH (A.U.C., R.G., T.S., S.R.).

Contrast-enhanced magnetic resonance angiography (MRA) provides excellent assessment of the peripheral arterial vasculature and is considered an important adjunctive diagnostic modality for the assessment of peripheral arterial disease. However, given the high prevalence of chronic kidney disease in patients with peripheral arterial disease, the association of gadolinium contrast media with nephrogenic systemic fibrosis, and recent concern with consequences of long-term deposition of gadolinium in the brain, there has been a renewed interest in noncontrast MRA approaches. Recent improvements in pulse sequences combined with instrumentation have facilitated the development of newer noncontrast MRA sequences that provide high spatial resolution, allowing the evaluation of distal (infrageniculate and pedal) vessels of importance in patients with critical limb ischemia. Read More

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.118.0088
Publisher Site
http://dx.doi.org/10.1161/CIRCIMAGING.118.008844DOI Listing
May 2019
6 Reads

Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors.

Toxicol Appl Pharmacol 2019 07 10;375:32-45. Epub 2019 May 10.

Kidney Institute of New Mexico and the University of New Mexico Department of Medicine, United States of America; New Mexico Veterans Administration Health Care System, United States of America. Electronic address:

Evidence for gadolinium-based contrast agent- (GBCA-) induced disease continues to mount. Risk factors for gadolinium-induced systemic fibrosis are entirely unexplored. Obesity-related renal injury is characterized by activation of glomerular mesangial cells and podocyte damage with alteration of lipid metabolism/lipid accumulation in both cell types resulting in matrix accumulation and eventual progression to glomerulosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.taap.2019.05.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588162PMC
July 2019
6 Reads

Non-contrast-enhanced magnetic resonance imaging for visualization and quantification of endovascular aortic prosthesis, their endoleaks and aneurysm sacs at 1.5 T.

Magn Reson Imaging 2019 07 7;60:164-172. Epub 2019 May 7.

Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein (UKSH), Kiel University, Kiel, Germany.

Purpose: After an endovascular aortic aneurysm repair (EVAR), a follow-up at 1, 6 and every 12 months is recommended for remainder of the patient's life. The diagnostic standard methods for diagnosing endoleaks and visualization of aneurysms in EVAR-patients are: invasive digital subtraction angiography (DSA), contrast enhanced (CE) computed tomographic angiography (CE-CTA), and magnetic resonance angiography (CE-MRA). These techniques, however, require the use of iodine- or gadolinium-based contrast agents with rare, but possibly life threatening side effects such as renal impairment, thyrotoxicosis and allergic reactions, nephrogenic systemic fibrosis, and cerebral gadolinium deposition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mri.2019.05.012DOI Listing
July 2019
9 Reads

Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study.

Acta Radiol 2019 Nov 26;60(11):1450-1456. Epub 2019 Apr 26.

Department of Pediatric Radiology, Women-Mother and Child Hospital, Hospices Civils de Lyon, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0284185119840649DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826856PMC
November 2019
2 Reads

[Kidney function in contrast media-enhanced imaging].

Radiologe 2019 May;59(5):425-434

Klinik für Nephrologie, Universitätsklinikum Essen, Universität Duisburg Essen, Hufelandstr. 55, 45147, Essen, Deutschland.

Background: The potential adverse reactions to contrast media-enhanced imaging regularly offer challenges in decision-making for nephrologists and radiologists.

Objective: The clinical pictures of contrast media-induced acute kidney injury (CI-AKI) and nephrogenic systemic fibrosis (NSF) were evaluated, which are both caused by contrast media and closely linked to the kidney function.

Material And Methods: The literature in PubMed and Medline was searched for the terms "kidney function" and "contrast media" and complemented by our own experiences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00117-019-0529-2DOI Listing
May 2019
5 Reads

Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.

J Invest Dermatol 2019 10 9;139(10):2134-2143.e2. Epub 2019 Apr 9.

Kidney Institute of New Mexico, Albuquerque, New Mexico, USA; University of New Mexico Health Science Center, Albuquerque, New Mexico, USA; New Mexico Veterans Administration Health Care System, Albuquerque, New Mexico, USA. Electronic address:

Gadolinium-based contrast agents are implicated in several pathologic abnormalities (long-term retention in vital organs such as the skin and the brain) and are the cause of a sometimes fatal condition in patients, nephrogenic systemic fibrosis. Bone marrow-derived fibrocytes and the monocyte chemoattractant protein-1 inflammatory pathway have been implicated as mediators of the adverse effects induced by gadolinium-based contrast agents. Mechanistic studies are scant; therefore, a mouse model of nephrogenic systemic fibrosis was established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2019.03.1145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756957PMC
October 2019
18 Reads

Update on Gadolinium-Based Contrast Agent-Enhanced Imaging in the Genitourinary System.

AJR Am J Roentgenol 2019 Apr 11:1-11. Epub 2019 Apr 11.

3 Department of Radiology, The University of Michigan, Ann Arbor, MI.

Objective: The purpose of this article is to review gadolinium-based contrast agent (GBCA)-enhanced MRI applications in the genitourinary system.

Conclusion: Nephrogenic systemic fibrosis is rare or nonexistent with standard dosing of group II GBCAs. Gadolinium retention, cost, and examination times are emerging considerations affecting GBCA use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.19.21137DOI Listing
April 2019
5 Reads

[Gadolinium deposition-"gadolinium deposition disease"].

Radiologe 2019 May;59(5):435-443

Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum des Saarlandes, Kirrberger Str., Gebäude 50.1, 66421, Homburg/Saar, Deutschland.

Gadolinium (Gd)-based contrast agents have been routinely used worldwide in diagnostic MRI since 1988. All routinely applied contrast agents for clinical use were considered extremely safe with regard to tolerance, adverse effects and diagnostic efficacy and when used at Food and Drug Administration-approved doses. With the identification of Gd-associated disorders, namely nephrogenic systemic fibrosis and adverse reactions, and in the longer term Gd-retention in the brain, this view changed and led to the withdrawal or restriction of approval of linear Gd chelates in Europe. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00117-019-0522-9
Publisher Site
http://dx.doi.org/10.1007/s00117-019-0522-9DOI Listing
May 2019
14 Reads

Effect of gadolinium concentration on temperature change under magnetic field.

PLoS One 2019 4;14(4):e0214910. Epub 2019 Apr 4.

Nazarbayev University, Chemical and Materials Engineering, Astana, Kazakhstan.

Gadolinium based contrast agents (GBCAs) were found to play a role in nephrogenic systemic fibrosis in patients with and without renal impairment. Therefore, preserving the structural stability of GBCAs to reduce their propensity to liberate Gd3+ is of utmost importance. This study evaluates the effect of gadolinium concentration of GBCAs on solution temperature under magnetic fields. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214910PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449068PMC
December 2019
7 Reads

Practical administration of intravenous contrast media in children: screening, prophylaxis, administration and treatment of adverse reactions.

Pediatr Radiol 2019 04 29;49(4):433-447. Epub 2019 Mar 29.

Department of Radiology, Boston Children's Hospital, Boston, MA, USA.

Administration of intravenous contrast media to children is a routine practice at many clinical imaging centers, that can involve special considerations. In this paper, we provide practical information to facilitate optimal performance and oversight of this task. We provide targeted screening questions that can help to identify high-risk pediatric patients for both iodine-based and gadolinium-based intravenous contrast media administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00247-018-4306-6DOI Listing
April 2019
11 Reads